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Abstract
Background: To assess the reporting of loss to follow-up (LTFU) information in articles on randomised controlled
trials (RCTs) with time-to-event outcomes, and to assess whether discrepancies affect the validity of study results.
Methods: Literature survey of all issues of the BMJ, Lancet, JAMA, and New England Journal of Medicine published
between 2003 and 2005. Eligible articles were reports of RCTs including at least one Kaplan-Meier plot. Articles were
classified as “assessable” if sufficient information was available to assess LTFU. In these articles, LTFU information was
derived from Kaplan-Meier plots, extracted from the text, and compared. Articles were then classified as “consistent”
or “not consistent”. Sensitivity analyses were performed to assess the validity of study results.
Results: 319 eligible articles were identified. 187 (59%) were classified as “assessable”, as they included sufficient
information for evaluation; 140 of 319 (44%) presented consistent LTFU information between the Kaplan-Meier plot
and text. 47 of 319 (15%) were classified as “not consistent”. These 47 articles were included in sensitivity analyses.
When various imputation methods were used, the results of a chi
2-test applied to the corresponding 2 × 2 table
changed and hence were not robust in about half of the studies.
Conclusions: Less than half of the articles on RCTs using Kaplan-Meier plots provide assessable and consistent
LTFU information, thus questioning the validity of the results and conclusions of many studies presenting survival
analyses. Authors should improve the presentation of both Kaplan-Meier plots and LTFU information, and reviewers
of study publications and journal editors should critically appraise the validity of the information provided.
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Background
Kaplan-Meier plots are frequently used in articles on
studies analysing survival (time-to-event) data. The corre-
sponding key paper by Kaplan and Meier [1] is one of the
most frequently cited statistical articles [2] (34,191 cita-
tions in ISI Web of Knowledge
®, http://www.isiknowledge.
com, 22.09.2010). The Kaplan-Meier method estimates the
probability of survival at a given time point for a member
of the population from which the sample is drawn [3], tak-
ing into account patients who did not experience the
event (outcome) of interest. These patients are classified
as censored. Censoring may occur if a patient reaches the
planned end of study, or is lost to follow-up [4]. A Kaplan-
Meier analysis is only unbiased if the main assumptions
hold that firstly, survival probabilities are the same at any
given point in time both for patients who are censored
and those who continue the study, and secondly, survival
probabilities are the same independent of the time of
recruitment [3].
Recommendations for the presentation and interpreta-
tion of survival plots are given in the literature. For exam-
ple, key information on follow-up can be presented by
displaying the numbers still at risk of the event in each
treatment group [5]
,[6], by giving a summary measure of
follow-up (e.g. median or range of follow-up) [5]
,[6], and
by marking the times of censored observations on the
survival curve in smaller studies [6]. However, despite
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lyses published in medical journals have shown substantial
reporting deficits [7-9].
We also found reporting deficits in studies presenting
survival analyses included in reports from our Institute
[10,11], i.e. inconsistencies between loss to follow-up
(LTFU) information derived from Kaplan-Meier plots and
reported in the text of study publications. Large numbers
of LTFU patients create the problem of increasing the
variance of estimated treatment effects. Unequal LTFU
proportions between groups raise doubts about the con-
duct of the study and hence the validity of the results.
The main objective of this survey is to assess the consis-
tency of LTFU information derived from Kaplan-Meier
plots and reported in the text of articles on randomised
controlled trials (RCTs) in four leading general medical
journals. We also assessed the impact of discrepancies in
LTFU information on the validity of study results.
It should be noted that there is great variability concern-
ing the definition of LTFU [12]. In the Cochrane glossary
this term is defined as “the loss of participants during the
course of a study” (and also called “attrition” or “drop-
outs”) [13]. Following this definition, in the present publi-
cation we use this term for any patient who “was lost” i.e.
discontinued the study prematurely for any reason.
Methods
A sensitive search of PubMed was performed to identify
RCTs published in four leading medical journals between
1 January 2003 and 31 December 2005 (BMJ, JAMA, Lan-
cet, and the New England Journal of Medicine [NEJM]).
The search was limited to citations with abstracts. The
search strategy is available in Additional file 1.
A l lf u l lt e x t so fr e t r i e v e dR C T sw e r et h e ns c r e e n e dt o
identify eligible articles, i.e. RCTs including at least one
Kaplan-Meier plot presenting a comparison of two or
more therapies. One Kaplan-Meier plot from each eligible
article was assessed, preferably a plot displaying the out-
come “all-cause mortality” (or a composite outcome
including all-cause mortality). If no mortality outcome was
reported, the primary endpoint was used.
Data were extracted using an extraction form that is
available from the authors on request. The items extracted
were: (1) definition and number of events of interest and
competing events; (2) information on numbers of patients
(for each group separately, if possible) (a) randomised, (b)
analysed, (c) with incomplete follow-up, and (d) at risk; (3)
minimum duration of follow-up (preferably the actual
duration, or if not available, either the duration estimated
by means of the period between end of enrolment and end
of study or the planned duration).
In articles including information on all items above, the
numbers of LTFU patients in each group can be inferred
from the Kaplan-Meier plot if numbers at risk are given
at a time point before minimum follow-up. These articles
were classified as “assessable”. In some articles details on
LTFU can also be inferred even if information on some
items is missing. For instance, in small studies each
patient can be identified in the plot. These articles were
also classified as “assessable”. The remaining publications
were classified as “not assessable”.
Assessable articles underwent further evaluation: At the
last time point with information on numbers at risk
before the time of minimum follow-up (“time point t”),
the survival probability was read from the curve. As no
patient should be censored before time point t, the
Kaplan-Meier curve represents 1 minus the empirical
failure distribution function. The numbers of patients
who still ought to be at risk at time point t can be calcu-
lated by multiplying the survival probability with the
number of randomised patients (see Figure 1 for an
example calculation). If the calculated number of patients
at risk was higher than the numbers at risk reported in
the figure legend, we tried to solve this discrepancy by
considering information on LTFU reported in the text. If
the outcome of interest was not “all-cause mortality” (or
a composite outcome including all-cause mortality), the
number of competing events was also considered. Arti-
cles were then classified as “consistent” if the numbers
calculated matched the reported numbers at risk. If
Figure 1 Recalculation of the numbers at risk - example
classified as “consistent”. Kaplan-Meier plot of a randomised trial
comparing prednisolone and a control group [4]. According to the
information in the text of the publication, one patient was lost to
follow-up in the prednisolone group and minimum follow-up was
120 days. At one time point beforehand (90 days), we read the
survival probability from the curve (see vertical line). We recalculated
the number of patients at risk by multiplying the survival probability
with the number of randomised patients (number at risk: 17 in the
prednisolone group vs. 6 in the control group). As the calculated
and reported numbers matched (taking into account the one
patient lost to follow-up in the prednisolone group), this example
would be classified as “consistent”.
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t i o nd e r i v e df r o mt h ep l o ta n dg i v e ni nt h et e x to r
if LTFU information could be derived from the plot and
no further information was provided in the text or the
calculated number at risk was larger than the reported
one, the articles were classified as “not consistent” (see
Figure 2 for an example calculation).
All articles were assessed by either EV or MK. A sub-
set of articles (those published in 2005) was assessed by
both authors and no relevant discrepancies in the
assessment were noted. Articles that were classified as
“not consistent” and articles where classification was
initially unclear were reassessed by a second reviewer
(MK, EV, TK, or GS). Disagreement was resolved by
consensus.
In order to evaluate the robustness and validity of study
results, sensitivity analyses were performed for all study
publications classified as “not consistent”.I nt h e s ep u b l i -
cations we calculated a higher number of patients at risk
than was reported in the Kaplan-Meier plot and which
could not be explained by the reported LTFU. We aimed
to assess the potential risk of bias caused by this discre-
pancy. For this purpose, we generated a 2 × 2 contin-
g e n c yt a b l ef o rt i m ep o i n tt( o n et i m ep o i n tb e f o r e
minimum follow-up, as defined above) by calculating the
number of events of interest up to this time and then
performed a c
2-test. We generated a second contingency
table where the difference between calculated and
reported numbers at risk, minus the reported LTFU, was
imputed (unreported LTFU). If no LTFU were reported
their number was assumed to be zero and the total differ-
ence was imputed. We classified a treatment effect as
“robust” if the effect estimate did not change direction
and the corresponding p-value remained significant or
not significant (a = 5%) after imputation. In the equal-
case scenario, the unreported LTFU data were imputed
as “event” in both groups. In the worst-case scenario,
unreported LTFU data were imputed as “event” in the
test group and “no event” in the control group (best-case
scenario: vice versa).
Results
Of 734 articles on RCTs, 319 were eligible for inclusion
(Figure 3). Of these 319 articles, 187 (59%) were classi-
fied as “assessable”, as they included sufficient informa-
tion for the assessment of LTFU; 132 articles (41%)
were not assessable.
140 of 319 articles (44%) presented consistent LTFU
information between the Kaplan-Meier plot and the
text. 47 (15%) were classified as “not consistent”,e i t h e r
because a higher rate of LTFU was derived from the
plot than was presented in the text (18 of 319 articles;
6%) or the LTFU information could be derived from the
plot but no further information was found in the text
(29 of 319 articles; 9%).
These 47 articles were included in the sensitivity ana-
lyses. When an equal-case scenario was used as an
imputation method, the results changed and hence were
n o tr o b u s ti n2 1( 4 5 % )o ft h e s es t u d i e s( t a b l e1 ) .A s
expected this proportion was even higher in the best-
and worst-case scenario (55% and 57% respectively;
table 1).
The journals reporting the fewest and the most
Kaplan-Meier plots were the BMJ (14 of 319; 4%) and
Figure 2 Recalculation of the numbers at risk - example
classified as “not consistent”. Kaplan-Meier plot of the trial
presented in figure 1, but using fictive data. In this example it is
assumed that no patient was reported as lost to follow-up in either
group and minimum follow-up was 120 days. As in figure 1, we
read the survival probability from the curve at 90 days. We
multiplied the survival probability by the number of randomized
patients in order to recalculate the number of patients at risk
(number at risk: 19 in the prednisolone group vs. 13 in the control
group). As the reported number at risk was smaller in the
prednisolone group, four patients must have been censored before
day 90. As no losses to follow up were reported, this fictive
example would be classified as “not consistent”.
Figure 3 Main results of the assessment of Kaplan-Meier plots
in articles on randomised controlled trials (RCTs).
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Page 3 of 5the NEJM (138 of 319; 43%) respectively (table 2). The
proportion of articles classified as “not assessable” varied
from 19% in JAMA and 93% in the BMJ, the latter find-
ing being due to the fact that, with one exception, plots
presented in the BMJ did not report numbers at risk in
the figure. In the remaining journals the proportion of
articles classified as “consistent” ranged from 33%
(NEJM) to 64% (JAMA).
Discussion
In this survey of over 300 articles on RCTs published in
four leading medical journals and using Kaplan-Meier
plots, less than half of the studies presented assessable and
consistent LTFU information. This poor reporting of
items of survival analyses is in line with the results of pre-
vious research. Reviews of articles on cancer trials present-
ing survival analyses found that less than 10% of articles
reported survival outcomes optimally [8], and only about
half included any summary of length of follow-up [7].
Regarding the reporting of LTFU, only about a quarter of
articles mentioned whether LTFU occurred or not and if
LTFU information was given, only about half of the arti-
cles stated how they were treated in the analyses [7].
Another problem in papers using survival analyses is
that they frequently do not account for competing risks
[8]. In the case of competing risks the Aalen-Johansen
estimator should be preferred to the Kaplan-Meier estima-
tor [14]. When competing events are censored, the
Kaplan-Meier curve cannot be interpreted as probabilities
[15] and may produce inconsistent information on LTFU.
It would therefore be interesting to investigate how many
articles in major medical journals deal adequately with
competing risks. However, the focus of this paper was
only on the reporting quality of LTFU information.
A part of the eligible pool of articles was originally
assessed by only one reviewer. However, articles where
classification was initially unclear and articles classified as
“not consistent” were always checked by a second
reviewer; by minimising the number of wrong allocations
to this category we thus consider our findings to be con-
servative. Contacting study authors might have been help-
ful in clarifying some of the inconsistencies found;
however, as our focus was on the reporting quality of sur-
vival analyses in published articles, no contact was made.
Nevertheless, within the framework of our regular work
we were able to verify inconsistencies in three publications
included in the survey. In two cases we had access to the
full clinical study report. In the third case, the author
informed us that the inconsistency was due to a mistake in
the editorial processing of the Kaplan-Meier plot.
Several recommendations for improving the numerical
and graphical presentation of survival analyses have been
provided in the literature [5,6,16]. Additional methods to
support data presentation have also been proposed: for
example, Royston et al. [17] developed an approach to
illustrate the distribution of observed and censored survi-
val times; Clark et al. [18] suggested a completeness index
to quantify the effect of LTFU, which could be helpful in
identifying possible bias caused by unequal follow-up.
Another approach to increase the quality of survival data
could be the improvement of study design to increase pro-
tocol adherence, e.g. inclusion of run-in periods to identify
non-compliant patients [19]. The reasons for LTFU or
missing data should always be provided, as depending on
the reason (e.g. worsening of disease), different imputation
methods may be required [20].
The CONSORT explanation and elaboration document
extended its recommendations on the reporting of follow-
up time in 2010, and in addition to stating the median
duration of follow-up, now also recommends stating the
minimum and maximum duration [21]. We suggest that
CONSORT should also recommend reporting the num-
bers at risk and competing events, as well as provide some
advice on the numerical and graphical presentation of
survival analyses to help authors present these data appro-
priately. As already suggested in relation to CONSORT
[22], we also propose that in their instructions for authors,
journals should be more explicit as to the extent to which
authors should adhere to specific recommendations.
The LOST to follow-up Information in Trials (LOST-
IT) study is currently being conducted with the primary
objective of assessing the potential impact of LTFU on the
estimates of treatment effect in RCTs with binary out-
comes [23]. This study is expected to have important
implications for trialists and users of the medical literature
Table 1 Change in study results* after imputation of
censored data
Imputation method
Original treatment effect N Equal case
n (%)
Best case
n (%)
Worst case
n (%)
Significant 24 8 (33) 7 (29) 9 (38)
Not significant 23 13 (57) 19 (83) 18 (78)
Total 47 21 (45) 26 (55) 27 (57)
* After imputation of censored data the effect estimate changed direction and
the corresponding p-value changed from significant to not significant or vice
versa (a = 5%).
Table 2 Results of the assessment of LTFU information
stratified by journal
BMJ JAMA Lancet NEJM Total
Articles (n) 14 70 97 138 319
Not assessable* (n (%)) 13 (93) 13 (19) 32 (33) 74 (54) 132 (41)
Consistent** (n (%)) 1 (7) 45 (64) 49 (51) 45 (33) 140 (44)
Not consistent (n (%)) 0 12 (17) 16 (16) 19 (14) 47 (15)
* Loss to follow-up information cannot be derived from the Kaplan-Meier plot.
** The numbers derived from the Kaplan-Meier plot matched the reported
numbers at risk.
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a consequence of LOST-IT [23].
Conclusions
Our survey shows that less than half of the articles on
RCTs using Kaplan-Meier plots provide assessable and
consistent LTFU information, thus questioning the
validity of the results and conclusions of many studies
presenting survival analyses. Authors should improve
the presentation of both Kaplan-Meier plots and infor-
mation on LTFU, and reviewers of study publications
and journal editors should critically appraise the validity
of the information provided.
Additional material
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